Qiagen (NYSE:QGEN) Shares Acquired by Jennison Associates LLC

Jennison Associates LLC lifted its position in shares of Qiagen (NYSE:QGEN) by 5.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,426,392 shares of the company’s stock after purchasing an additional 68,415 shares during the period. Jennison Associates LLC’s holdings in Qiagen were worth $65,001,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Victory Capital Management Inc. increased its holdings in shares of Qiagen by 104,759.6% in the 2nd quarter. Victory Capital Management Inc. now owns 1,583,380 shares of the company’s stock valued at $65,061,000 after acquiring an additional 1,581,870 shares during the last quarter. Earnest Partners LLC boosted its holdings in Qiagen by 85.1% in the first quarter. Earnest Partners LLC now owns 3,427,605 shares of the company’s stock valued at $147,353,000 after purchasing an additional 1,576,259 shares in the last quarter. Nuance Investments LLC increased its stake in Qiagen by 17.3% in the second quarter. Nuance Investments LLC now owns 5,271,494 shares of the company’s stock valued at $216,606,000 after purchasing an additional 778,005 shares during the last quarter. Point72 Asset Management L.P. raised its holdings in Qiagen by 148.8% during the second quarter. Point72 Asset Management L.P. now owns 1,184,806 shares of the company’s stock worth $48,684,000 after purchasing an additional 708,533 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its position in shares of Qiagen by 12.2% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 3,248,354 shares of the company’s stock worth $133,292,000 after buying an additional 353,280 shares during the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on QGEN. Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research report on Thursday, October 17th. Robert W. Baird raised their price objective on Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Finally, HSBC downgraded Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price for the company. in a report on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Qiagen presently has an average rating of “Moderate Buy” and an average target price of $50.88.

Qiagen Stock Performance

NYSE QGEN opened at $42.11 on Thursday. The stock has a market capitalization of $9.61 billion, a price-to-earnings ratio of 107.97, a PEG ratio of 3.16 and a beta of 0.41. The business’s 50 day moving average is $43.57 and its two-hundred day moving average is $43.73. Qiagen has a 12-month low of $39.03 and a 12-month high of $47.44. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.